optometryadvisor9m
SGLT2 Inhibitors Reduce the Risk for Dementia, PD in Patients With Diabetes
The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.
Pharmabiz7h
Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer
Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer: Princeton, New Jersey Monday, November 18, 2 ...
Nurix Therapeutics Presents Preclinical Data From Two Autoimmune And Inflammatory Disease Programs, NX-5948 And GS-6791, At ACR Convergence 2024
Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in sel ...
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell ...
Le Lézard3h
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Tharimmune, Inc. ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of ...
STAT16h
Syndax wins U.S. approval for leukemia treatment
The pill, called Revuforj, is the first medicine in a class of drugs called menin inhibitors to reach the market. Revuforj ...
Business Wire2h
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developi ...